Phase I trial evaluating ACCG-2671
Latest Information Update: 25 Sep 2025
At a glance
- Drugs ACCG 2671 (Primary)
- Indications Obesity
- Focus Adverse reactions
Most Recent Events
- 06 Aug 2025 According to Structure Therapeutics media release, company plans to initiate a first-in-human Phase 1 clinical study by year-end 2025.
- 23 Dec 2024 New trial record